Low-dose genistein induces cyclin-dependent kinase inhibitors and G1 cell-cycle arrest in human prostate cancer cells

Molecular Carcinogenesis

Volumn 29, Issue 2, 2000, Pages 92-102

  Shen, J C ^a   Klein, Russell D ^b   Wei, Qingyi ^a   Guan, Yongli ^a   Contois, John H ^a   Wang, Thomas T Y ^c   Chang, Shine ^a   Hursting, Stephen D ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c BELTSVILLE HUMAN NUTRITION RESEARCH CENTER   (United States)

Author keywords

Isoflavone; LNCaP; p21(WAF1); p27(KIP1)

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; GENISTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL VIABILITY; DOSE RESPONSE; DRUG EFFECT; ENVIRONMENTAL FACTOR; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL COUNT; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; DOSE-RESPONSE RELATIONSHIP, DRUG; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, CDC; GENES, TUMOR SUPPRESSOR; GENISTEIN; GROWTH INHIBITORS; HUMANS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0033763830     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-2744(200010)29:2<92::AID-MC6>3.0.CO;2-Q     Document Type: Article

References (56)

1. Prostatic cancer: Some epidemiological features
2. Cancer statistics
3. Preliminary study of the frequency of benign prostatic hyperplasia and prostate cancer in China
4. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County
5. Prostate cancer in relation to diet, physical activity and body size in blacks, whites and Asians in the U.S. and Canada
6. Environmental factors and cancer incidence and mortality in different countries with special reference to dietary practice
7. Types of dietary fat and the incidence of cancer at five sites
8. Soy, its components, and cancer prevention: A review of the in vitro, animal and human data
9. Effect of genistein on in vitro and in vivo models of cancer
10. Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet
11. The identification and measurement of phytoestrogens in human saliva, plasma, breast aspirate or cyst fluid, and prostatic fluid using gas chromatography-mass spectrometry
12. Development of a database for assessing dietary phytoestrogen intake
13. Case-control assessment of dietary phytoestrogen intake and the risk of prostate cancer
14. An in vitro and in vivo study of antitumor effects of genistein on hormone refractory prostate cancer
15. Dietary soybean may be antiestrogenic in male mice
16. Influence of isoflavones in soy protein isolates on development of induced prostate-related cancers in L-W rats
17. Soy and rye diets inhibit the development of Dunning R3327 prostatic adenocarcnoma in rats
18. Genistein, a specific inhibitor of tyrosine-specific protein kinases
19. Effect of genistein on topoisomerase activity and on the growth of [Val 12] Ha-ras-transformed NIH 3T3 cells
20. Genistein, a dietary-derived inhibitor of in vitro angiogenesis
21. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice
22. Protein-tyrosine kinase inhibition: Mechanism-based discovery of antitumor agents
23. Inhibition of PDGF-induced c-jun and c-fos expression by a tyrosine protein kinase inhibitor
24. Effect of the tyrosine kinase inhibitor, genistein, on interleukin-1 stimulated PGE2 production in mesangial cells
25. Genistein-induced upregulation of p21, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells
26. Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity
27. Genistein inhibits proliferation and in vitro invasion potential of human prostatic cancer cell lines
28. Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation
29. Effects of soybean isoflavones on cell growth and apoptosis of the human prostatic cancer cell line LNCaP
30. Inhibition of prostate specific antigen expression by genistein in prostate cancer cells
31. Application of the MTT assay to human prostate cancer cell lines in vitro: Establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects
32. Mechanistic studies of the effects of the retinoid N-(4-hydroxyphenyl)-retinamide on prostate cancer cell growth and apoptosis
33. Effects of dehydroepiandrosterone and calorie restriction on the Bcl-2/ Bax-mediated apoptotic pathway in p53-deficient mice
34. Simultaneous amplification of four DNA repair genes in lymphocytes by multiplex reverse transcription-polymerase chain reaction
35. Genistein inhibits the growth of human-patient BPH and prostate cancer in histoculture
36. Effects of genistein on the growth and cell cycle progression of normal human lymphocytes and human leukemic MOLT-4 and HL-60 cells
37. The natural tyrosine kinase inhibitor genistein produces cell cycle arrest and apoptosis in Jurkat T-leukemia cells
38. Plasma concentrations of phytoestrogens in Japanese men
39. Multiple roles of the proliferating cell nuclear antigen: DNA replication, repair and cell cycle control
40. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA
41. Increased UDP-glucuronyltransferase activity and decreased prostate specific antigen production by Biochanin A in prostate cancer cells
42. Prognostic value and expression of p21 (waf1/cip1) protein in prostate cancer
43. Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21 (waf1/cip1)
44. Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: Implications for prostate cancer intervention
45. Proliferation and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: Prognostic significance of p21/WAF1/CIP1 expression
46. Antiproliferative effect of 1-alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase-2 activity and persistent G1 accumulation
47. Expression of p27(KIP1) in prostatic adenocarcinoma
48. Association of p27/Kip1 levels with recurrence and survival in paients with stage C prostate carcinoma
49. Loss of the cyclin-dependent kinase inhibitor p27(kip1) protein in human prostate cancer correlates with tumor grade
50. Distinct altered patterns of p27(KIP1) gene expression in benign prostatic hyperplasia and prostatic carcinoma
51. A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells
52. Novel 20-epivitamin D3 analog combined with 9-cis retinoic acid markedly inhibits colony growth of prostate cancer cells
53. The role of soy products in reducing risk of cancer
54. Dietary effects on breast cancer risk in Singapore
55. Lifestyle and cancer: From epidemiological evidence to public behavior change to mortality reduction of target cancers
56. A prospective study of demographics, diet and prostate cancer among men of Japanese ancestry in Hawaii